January 11, 2019European Heart Journal
Assessing the severity of acute pulmonary embolism: back to the future?
Why the study?
Does the presence of right ventricular dysfunction or elevated cardiac biomarkers predict early mortality in patients with acute pulmonary embolism classified as low-risk by clinical scores?
Population
Patients with acute pulmonary embolism, specifically those classified as low-risk by clinical scores
Comparison
Assessment of right ventricular dysfunction or… vs Clinical assessment alone
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
This editorial argues that clinical risk scores alone are insufficient for identifying low-risk pulmonary embolism patients suitable for home treatment, advocating for the inclusion of imaging or biomarker assessment of right ventricular function.
Structured PICO
Does the presence of right ventricular dysfunction or elevated cardiac biomarkers predict early mortality in patients with acute pulmonary embolism classified as low-risk by clinical scores?
P
Population
Patients with acute pulmonary embolism, specifically those classified as low-risk by clinical scores (e.g., PESI, sPESI)
I
Intervention
Assessment of right ventricular dysfunction or myocardial injury using imaging (echocardiography, CT) or cardiac biomarkers (troponin, natriuretic peptides)
C
Comparator
Clinical assessment alone
O
Outcome
Early mortalityhard clinical
This editorial argues that clinical risk scores alone are insufficient for identifying low-risk pulmonary embolism patients suitable for home treatment, advocating for the inclusion of imaging or biomarker assessment of right ventricular function.
Cite This Study
Adam Torbicki (2019) studied this question.